Dual Corneal-Graft Rejection after mRNA Vaccine (BNT162b2) for COVID-19 during the First Six Months of Follow-Up: Case Report, State of the Art and Ethical Concerns

Present mass vaccination against Coronavirus Disease-19 (COVID-19) is the most widely used health policy and the most promising approach to curb the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic globally. However, new side effects are emerging from the mass vaccination not de...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Matteo Nioi, Ernesto d’Aloja, Maurizio Fossarello, Pietro Emanuele Napoli
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	COVID-19 BNT162b2 vaccine BNT162b2 vaccine side effect COVID-19 vaccines corneal graft COVID-19 vaccines transplant rejection COVID-19 vaccines and corneal graft rejection Medicine R
Acceso en línea:	https://doaj.org/article/23932dc237a1497182bc822524614c1e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:23932dc237a1497182bc822524614c1e
record_format	dspace
spelling	oai:doaj.org-article:23932dc237a1497182bc822524614c1e2021-11-25T19:10:50ZDual Corneal-Graft Rejection after mRNA Vaccine (BNT162b2) for COVID-19 during the First Six Months of Follow-Up: Case Report, State of the Art and Ethical Concerns10.3390/vaccines91112742076-393Xhttps://doaj.org/article/23932dc237a1497182bc822524614c1e2021-11-01T00:00:00Zhttps://www.mdpi.com/2076-393X/9/11/1274https://doaj.org/toc/2076-393XPresent mass vaccination against Coronavirus Disease-19 (COVID-19) is the most widely used health policy and the most promising approach to curb the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic globally. However, new side effects are emerging from the mass vaccination not described during the experimental stages. In the present study, we discuss a case of acute corneal graft rejection, which has occurred 25 years after transplantation and 13 days after the administration of the BNT162b2 vaccine (Comirnaty, BioNTech/Pfizer), which was followed-up for a period of six months. In this period, the corneal inflammation appeared twice but was successfully managed with topical therapy and supplementation of Vitamin D. A risk of corneal graft rejection must be included in the list of potential vaccine complications, in order to inform the transplanted patient to undergo a preliminary and a follow-up ocular examination, and eventually to include corneal graft in the list of contraindications to vaccination.Matteo NioiErnesto d’AlojaMaurizio FossarelloPietro Emanuele NapoliMDPI AGarticleCOVID-19BNT162b2 vaccineBNT162b2 vaccine side effectCOVID-19 vaccines corneal graftCOVID-19 vaccines transplant rejectionCOVID-19 vaccines and corneal graft rejectionMedicineRENVaccines, Vol 9, Iss 1274, p 1274 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	COVID-19 BNT162b2 vaccine BNT162b2 vaccine side effect COVID-19 vaccines corneal graft COVID-19 vaccines transplant rejection COVID-19 vaccines and corneal graft rejection Medicine R
spellingShingle	COVID-19 BNT162b2 vaccine BNT162b2 vaccine side effect COVID-19 vaccines corneal graft COVID-19 vaccines transplant rejection COVID-19 vaccines and corneal graft rejection Medicine R Matteo Nioi Ernesto d’Aloja Maurizio Fossarello Pietro Emanuele Napoli Dual Corneal-Graft Rejection after mRNA Vaccine (BNT162b2) for COVID-19 during the First Six Months of Follow-Up: Case Report, State of the Art and Ethical Concerns
description	Present mass vaccination against Coronavirus Disease-19 (COVID-19) is the most widely used health policy and the most promising approach to curb the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic globally. However, new side effects are emerging from the mass vaccination not described during the experimental stages. In the present study, we discuss a case of acute corneal graft rejection, which has occurred 25 years after transplantation and 13 days after the administration of the BNT162b2 vaccine (Comirnaty, BioNTech/Pfizer), which was followed-up for a period of six months. In this period, the corneal inflammation appeared twice but was successfully managed with topical therapy and supplementation of Vitamin D. A risk of corneal graft rejection must be included in the list of potential vaccine complications, in order to inform the transplanted patient to undergo a preliminary and a follow-up ocular examination, and eventually to include corneal graft in the list of contraindications to vaccination.
format	article
author	Matteo Nioi Ernesto d’Aloja Maurizio Fossarello Pietro Emanuele Napoli
author_facet	Matteo Nioi Ernesto d’Aloja Maurizio Fossarello Pietro Emanuele Napoli
author_sort	Matteo Nioi
title	Dual Corneal-Graft Rejection after mRNA Vaccine (BNT162b2) for COVID-19 during the First Six Months of Follow-Up: Case Report, State of the Art and Ethical Concerns
title_short	Dual Corneal-Graft Rejection after mRNA Vaccine (BNT162b2) for COVID-19 during the First Six Months of Follow-Up: Case Report, State of the Art and Ethical Concerns
title_full	Dual Corneal-Graft Rejection after mRNA Vaccine (BNT162b2) for COVID-19 during the First Six Months of Follow-Up: Case Report, State of the Art and Ethical Concerns
title_fullStr	Dual Corneal-Graft Rejection after mRNA Vaccine (BNT162b2) for COVID-19 during the First Six Months of Follow-Up: Case Report, State of the Art and Ethical Concerns
title_full_unstemmed	Dual Corneal-Graft Rejection after mRNA Vaccine (BNT162b2) for COVID-19 during the First Six Months of Follow-Up: Case Report, State of the Art and Ethical Concerns
title_sort	dual corneal-graft rejection after mrna vaccine (bnt162b2) for covid-19 during the first six months of follow-up: case report, state of the art and ethical concerns
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/23932dc237a1497182bc822524614c1e
work_keys_str_mv	AT matteonioi dualcornealgraftrejectionaftermrnavaccinebnt162b2forcovid19duringthefirstsixmonthsoffollowupcasereportstateoftheartandethicalconcerns AT ernestodaloja dualcornealgraftrejectionaftermrnavaccinebnt162b2forcovid19duringthefirstsixmonthsoffollowupcasereportstateoftheartandethicalconcerns AT mauriziofossarello dualcornealgraftrejectionaftermrnavaccinebnt162b2forcovid19duringthefirstsixmonthsoffollowupcasereportstateoftheartandethicalconcerns AT pietroemanuelenapoli dualcornealgraftrejectionaftermrnavaccinebnt162b2forcovid19duringthefirstsixmonthsoffollowupcasereportstateoftheartandethicalconcerns
_version_	1718410203383201792

Dual Corneal-Graft Rejection after mRNA Vaccine (BNT162b2) for COVID-19 during the First Six Months of Follow-Up: Case Report, State of the Art and Ethical Concerns

Ejemplares similares